IMGN Insider Trading Activity and SEC Form 4 Filings
IMGN insider trading summary
No open-market insider purchases or sales of ImmunoGen, Inc. (IMGN) have been reported on SEC Form 4 in the past 12 months.
Latest IMGN insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Feb 5, 2024 | Stacy Ann Coen | SVP & Chief Business Officer | Sell | $134K (4,583 @ $29.30) |
| Feb 5, 2024 | Theresa Wingrove | SVP of Regulatory Affairs | Sell | $352K (12,027 @ $29.30) |
| Feb 5, 2024 | Renee Lentini | VP & Prin Acctg Officer | Sell | $77K (2,631 @ $29.30) |
| Feb 5, 2024 | Mark J Enyedy | Chief Executive Officer | Sell | $589K (20,107 @ $29.28) |
| Jan 16, 2024 | Theresa Wingrove | SVP of Regulatory Affairs | Sell | $5.6M (187,667 @ $29.64) |
| Dec 26, 2023 | Renee Lentini | VP & Prin Acctg Officer | Sell | $195K (6,548 @ $29.74) |
| Dec 15, 2023 | Theresa Wingrove | SVP of Regulatory Affairs | Sell | $3.5M (117,445 @ $29.40) |
| Nov 30, 2023 | Kristine Peterson | Insider | Sell | $578K (20,000 @ $28.90) |
| Nov 30, 2023 | Theresa Wingrove | SVP of Regulatory Affairs | Sell | $4.8M (164,424 @ $28.95) |
| Nov 30, 2023 | Stacy Ann Coen | SVP & Chief Business Officer | Sell | $112K (3,826 @ $29.20) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.